Wall Street Zen Downgrades Kiniksa Pharmaceuticals International (NASDAQ:KNSA) to Buy

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was downgraded by stock analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Friday.

Other analysts have also issued reports about the stock. Wells Fargo & Company boosted their price target on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a research note on Thursday, September 25th. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Saturday, September 27th. TD Cowen started coverage on shares of Kiniksa Pharmaceuticals International in a research note on Monday, September 29th. They set a “buy” rating and a $60.00 target price on the stock. Jefferies Financial Group upped their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a “buy” rating in a research note on Tuesday, July 29th. Finally, Wedbush restated an “outperform” rating and set a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Seven analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International has a consensus rating of “Moderate Buy” and an average target price of $44.29.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ:KNSA opened at $38.49 on Friday. The firm has a market capitalization of $2.85 billion, a PE ratio of 962.49 and a beta of 0.16. The firm’s 50-day moving average is $34.49 and its two-hundred day moving average is $28.70. Kiniksa Pharmaceuticals International has a 1 year low of $17.82 and a 1 year high of $39.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.05. The company had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Analysts expect that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, COO Eben Tessari sold 42,000 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $38.33, for a total transaction of $1,609,860.00. Following the completion of the sale, the chief operating officer owned 34,552 shares in the company, valued at $1,324,378.16. This represents a 54.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Thomas Malley sold 78,233 shares of the company’s stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $33.09, for a total value of $2,588,729.97. Following the sale, the director owned 12,546 shares of the company’s stock, valued at $415,147.14. This trade represents a 86.18% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 603,371 shares of company stock valued at $20,434,869 over the last ninety days. 53.48% of the stock is owned by insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Large investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after purchasing an additional 532 shares during the last quarter. Osaic Holdings Inc. purchased a new stake in shares of Kiniksa Pharmaceuticals International during the second quarter worth approximately $31,000. GAMMA Investing LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock worth $27,000 after purchasing an additional 568 shares during the last quarter. US Bancorp DE purchased a new stake in shares of Kiniksa Pharmaceuticals International during the first quarter worth approximately $33,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Kiniksa Pharmaceuticals International during the second quarter worth approximately $43,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.